The place of selective serotonin reuptake inhibitors in the treatment of panic disorder

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 282-291

  DeVane, C Lindsay ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; FLUVOXAMINE; PAROXETINE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; PANIC; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SEROTONINERGIC TRANSMISSION;

EID: 0030982836     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994:397-403.
2. Eaton WW, Kessler RC, Wittchen H, Magee WJ. Panic and panic disorder in the United States. Am J Psychiatry 1994;151:413-20.
3. Katerndahl DA, Realini JP. Lifetime prevalence of panic states. Am J Psychiatry 1993;150:246-9.
4. Starcevic V, Uhlenhuth EH, Kellner R, Pathak D. Comorbidity in panic disorder. II. Chronology of appearance and pathogenic comorbidity. Psychiatry Res 1993;46:285-93.
5. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
6. Ballenger JC. Panic disorder: efficacy of current treatments. Psychopharmacol Bull 1993;29:477-86.
7. Tesar GE, Rosenbaum JF. Recognition and management of panic disorder. Adv Intern Med 1993;38:123-49.
8. Burrows GD, Judd FK, Norman TR. Long-term drug treatment of panic disorder. J Psychiatr Res 1993;27(suppl 1):111-25.
9. Noyes R Jr, Garvey MJ, Cook BL, Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989;50:163-9.
10. Keller MB, Hanks DL. Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:551-70.
11. Sheehan DV, Raj BA, Trehan RR, Knapp EL. Serotonin in panic disorder and social phobia. Int Clin Psychopharmacol 1993;8(suppl 2):63-77.
12. Kahn RS, Kalus O, Wetzler S, van Praag HM. The role of serotonin in the regulation of anxiety. In: Brown S, van Praag HM, eds. The role of serotonin in psychiatric disorders. New York: Brunner/Mazel, 1990:129-60.
13. Westenberg HGM, Den Boer JA. Treatment of panic disorder: evidence supporting the role of serotonin. In: Idzikowski C, Cowen PJ, eds. Serotonin, sleep, and mental disorder. Chicago: Wrightson Biomedical Publishing, 1991:147-60.
14. Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 1983;2:98-9.
15. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984;41:751-63.
16. Nutt D, Lawson C. Panic attacks: a neurochemical overview of models and mechanisms. Br J Psychiatry 1992;160:165-78.
17. Charney DS, Heninger GR. Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. Arch Gen Psychiatry 1985;42:458-67.
18. Charney DS, Heninger GR. Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. Arch Gen Psychiatry 1985;42:473-81.
19. Den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74.
20. Banki CM. Correlation of anxiety and related syndromes with cerebrospinal fluid 5-hydroindolacetic acid in depressed women. J Neural Transm 1977;41:135-43.
21. Eriksson E, Westberg P, Alling C, Thuresson K, Modigh K. Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res 1991;36:243-51.
22. Charney DS, Woods SW, Goodman WK, Heninger GR. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987;92:14-24.
23. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 1991;30:973-84.
24. Kahn RS, Asnis GM, Wetzler S, van Praag HM. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology (Berl) 1988;96:360-4.
25. Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E. A focal brain abnormality in panic disorder, a severe form of anxiety. Nature 1984;310:683-5.
26. Reiman EM, Raichle ME, Robins E, et al. The application of positron emission tomography to the study of panic disorder. Am J Psychiatry 1986;143:469-77.
27. Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-9.
28. Humble M, Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol 1992;6(suppl 5):21-39.
29. Roy-Byrne PP. Integrated treatment of panic disorder. Am J Med 1992;92(suppl 1A):49S-54.
30. Katerndahl DA, Realini JP. Where do panic attack sufferers seek care? J Fam Pract 1995;40:237-43.
31. Wittchen H, Essau CA. Epidemiology of panic disorder: progress and unresolved issues. J Psychiatr Res 1993;27(suppl 1):47-68.
32. Lepine JP, Chignon JM, Teherani M. Suicide attempts in patients with panic disorder. Arch Gen Psychiatry 1993;50:144-9.
33. Katon WJ, Von Korff M, Lin E. Panic disorder: relationship to high medical utilization. Am J Med 1992;92(suppl 1A):7S-11.
34. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psychiatry 1989;46:984-92.
35. Cowley DS. Alcohol abuse, substance abuse, and panic disorder. Am J Med 1992;92(suppl 1A):41S-8.
36. Andrade L, Eaton WW, Chilcoat H. Lifetime comorbidity of panic attacks and major depression in a population-based study: symptom profiles. Br J Psychiatry 1994;165:363-9.
37. Ware MR, Caton D, DeVane CL. The practical use of carbon dioxide-induced anxiety in the diagnosis and care of patients with panic disorder. Ann Clin Psychiatry 1996;8: 199-202.
38. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia. I. Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988;45:437-43.
39. Ballenger JC. Overview of panic disorder. Trans Am Clin Climatol Assoc 1993;105:36-51.
40. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-22.
41. Noyes R Jr, Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991;148:517-23.
42. Cross-National Collaborative Panic Study SP. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191-202.
43. Nemeroff CB, DeVane CL, Pollock GB. Antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153: 311-20.
44. Klerman GL. Treatments for panic disorder. J Clin Psychiatry 1992;53(suppl):14-19.
45. Ballenger JC, Pecknold J, Rickels K, Sellers EM. Medication discontinuation in panic disorder. J Clin Psychiatry 1993;54(suppl):15-21.
46. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51-60.
47. Cowley DS, Roy-Byrne PP, Radant A, et al. Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 1995;12:147-57.
48. Cohen LS, Rosenbaum JF. Clonazepam: new uses and potential problems. J Clin Psychiatry 1987;48(suppl):50-5.
49. Zitrin CM, Klein DF, Woerner MG. Behavior therapy, supportive psychotherapy, imipramine, and phobias. Arch Gen Psychiatry 1978;35:307-16.
50. Roy-Byrne PP, Vitaliano PP, Cowley DS, Luciano G, Zheng Y, Dunner DL. Coping in panic and major depressive disorder: relative effects of symptom severity and diagnostic comorbidity. J Nerv Ment Dis 1992;180:179-83.
51. Tyrer P. Current status of β-blocking drugs in the treatment of anxiety disorders. Drugs 1988;36:773-83.
52. Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983;3:28-31.
53. Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50.
54. Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-6.
55. Den Boer JA, Westenberg HGM. Serotonin function in panic disorder, a double-blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94.
56. Coplan JD, Papp LA, Martinez J, et al. Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 1995;152:619-22.
57. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-9.
58. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-9.
59. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-8.
60. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-9.
61. von Moltke LL, Greenblatt DJ, Cotrequ-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38:23-31.
62. Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry 1994;55:539-42.
63. Ware MR, DeVane CL. Successful treatment of panic disorder during pregnancy with imipramine. J Clin Psychiatry 1990;51:482-4.
64. Moreau D, Weissman MM. Panic disorder in children and adolescents: a review. Am J Psychiatry 1992;149:1306-14.
65. DeVane CL, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry 1996;57:55-62.